~ Buy the VENCLEXTA (venetoclax) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR VENCLEXTA

All Clinical Trials for Venclexta

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00501826 ↗	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Recruiting	GlaxoSmithKline	Phase 2	2007-07-11	This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT00501826 ↗	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2007-07-11	This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT00501826 ↗	Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Recruiting	M.D. Anderson Cancer Center	Phase 2	2007-07-11	This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT01794520 ↗	Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma	Active, not recruiting	Genentech, Inc.	Phase 1/Phase 2	2012-10-10	The phase 1 primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in participants with relapsed or refractory multiple myeloma. This study will also assess the safety profile and PK of venetoclax in combination with dexamethasone in participants with t(11;14)-positive multiple myeloma. The phase 2 primary objective is to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in participants with t(11;14)-positive multiple myeloma.

Clinical Trial Conditions for Venclexta

Condition Name

Condition Name for Venclexta
Intervention	Trials
Acute Myeloid Leukemia	52
Recurrent Acute Myeloid Leukemia	28
Refractory Acute Myeloid Leukemia	27
Chronic Lymphocytic Leukemia	25

Condition MeSH

Condition MeSH for Venclexta
Intervention	Trials
Leukemia	116
Leukemia, Myeloid, Acute	75
Leukemia, Myeloid	71
Leukemia, Lymphoid	48

Clinical Trial Locations for Venclexta

Trials by Country

Trials by Country for Venclexta
Location	Trials
United States	710
Japan	99
China	76
Australia	47
France	45

Trials by US State

Trials by US State for Venclexta
Location	Trials
Texas	76
Massachusetts	38
California	36
Ohio	33
New York	32

Clinical Trial Progress for Venclexta

Clinical Trial Phase

Clinical Trial Phase for Venclexta
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	15
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for Venclexta
Clinical Trial Phase	Trials
Recruiting	100
Not yet recruiting	54
Active, not recruiting	16

Clinical Trial Sponsors for Venclexta

Sponsor Name

Sponsor Name for Venclexta
Sponsor	Trials
National Cancer Institute (NCI)	75
AbbVie	47
M.D. Anderson Cancer Center	45

Sponsor Type

Sponsor Type for Venclexta
Sponsor	Trials
Other	155
Industry	128
NIH	75